Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou, China.
J Surg Oncol. 2012 Mar;105(3):293-6. doi: 10.1002/jso.22085. Epub 2011 Aug 31.
To identify clinicopathologic variables that could predict pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced gastric cancer.
The study enrolled 108 patients who underwent neoadjuvant chemotherapy followed by surgery between July 2004 and December 2010. Tumor responses to neoadjuvant chemotherapy were assessed in terms of tumor regression. Statistical analyses were performed to identify factors associated with pathologic tumor response.
Tumor regression was found in 22.2% (24/108) patients, patients with tumor regression observed better overall survival as compared to that of patients without tumor regression. Univariate and multivariate analyses observed that both tumor differentiation and tumor size were independent predictors of tumor regression.
This study suggests that both tumor differentiation and tumor size is the most important clinical predicator of pathologic tumor response, it may be of benefit in the selection of treatment options in locally advanced gastric cancer.
明确可能预测局部进展期胃癌患者接受新辅助化疗后病理肿瘤反应的临床病理变量。
该研究纳入了 108 例于 2004 年 7 月至 2010 年 12 月期间接受新辅助化疗加手术治疗的患者。根据肿瘤退缩程度评估新辅助化疗的肿瘤反应。采用统计学分析确定与病理肿瘤反应相关的因素。
22.2%（24/108）的患者出现肿瘤退缩，与无肿瘤退缩的患者相比，出现肿瘤退缩的患者总体生存情况更好。单因素和多因素分析观察到，肿瘤分化和肿瘤大小均是肿瘤退缩的独立预测因素。
本研究表明，肿瘤分化和肿瘤大小均是病理肿瘤反应的最重要临床预测因素，这可能有助于选择局部进展期胃癌的治疗方案。
